FierceBiotech: Biotech

An 'atlas' of the brain spurs discovery of new cells that could provide map for stroke, Alzheimer's treatments

Kyle LaHucik — Mon, 31 Jan 2022 18:23:27 +0000

An 'atlas' of the brain spurs discovery of new cells that could provide map for stroke, Alzheimer's treatments klahucik Mon, 01/31/2022 - 13:23

Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme

Kyle LaHucik — Mon, 31 Jan 2022 17:14:08 +0000

Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme klahucik Mon, 01/31/2022 - 12:14

Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts

Annalee Armstrong — Mon, 31 Jan 2022 14:33:56 +0000

Gamida Cell readies stem cell transplant therapy for FDA submission but seeks strategic partners amid staffing cuts aarmstrong Mon, 01/31/2022 - 09:33

Madrigal's NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data

Nick Paul — Mon, 31 Jan 2022 13:54:07 +0000

Madrigal's NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data ntaylor Mon, 01/31/2022 - 08:54

Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market

Nick Paul — Mon, 31 Jan 2022 13:04:43 +0000

Pfizer ends $3B drug dream despite phase 2b success, leaving Regeneron with a clear run at cardiovascular market ntaylor Mon, 01/31/2022 - 08:04

UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program

Kyle LaHucik — Fri, 28 Jan 2022 19:37:35 +0000

UPDATE: Kaleido confirms layoffs, halts planned phase 2 and appears to have ended COVID-19 program klahucik Fri, 01/28/2022 - 14:37

Charles River Labs deals with SAMDI Tech to boost discovery business

Gareth Macdonald — Fri, 28 Jan 2022 17:58:21 +0000

Charles River Labs deals with SAMDI Tech to boost discovery business aarmstrong Fri, 01/28/2022 - 12:58

Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug

Nick Paul — Fri, 28 Jan 2022 13:20:00 +0000

Yet another delay at Amryt as EMA calls in experts to inform review of rare disease drug ntaylor Fri, 01/28/2022 - 08:20

Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trials

Nick Paul — Fri, 28 Jan 2022 11:31:06 +0000

Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trials ntaylor Fri, 01/28/2022 - 06:31

Taysha mulls tweaks to gene therapy trial after subject dies

Nick Paul — Thu, 27 Jan 2022 13:45:05 +0000

Taysha mulls tweaks to gene therapy trial after subject dies ntaylor Thu, 01/27/2022 - 08:45

Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial

Nick Paul — Thu, 27 Jan 2022 12:23:04 +0000

Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trial ntaylor Thu, 01/27/2022 - 07:23

9-year J&J science chief Stoffels to steer Galapagos' rebound as CEO

Kyle LaHucik — Wed, 26 Jan 2022 21:35:37 +0000

9-year J&J science chief Stoffels to steer Galapagos' rebound as CEO klahucik Wed, 01/26/2022 - 16:35

Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder

Kyle LaHucik — Wed, 26 Jan 2022 20:34:52 +0000

Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder klahucik Wed, 01/26/2022 - 15:34

Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit

Nick Paul — Wed, 26 Jan 2022 11:49:10 +0000

Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exit ntaylor Wed, 01/26/2022 - 06:49

Gilead's $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47

Nick Paul — Wed, 26 Jan 2022 10:49:20 +0000

Gilead's $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47 ntaylor Wed, 01/26/2022 - 05:49

Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising

Annalee Armstrong — Tue, 25 Jan 2022 19:00:32 +0000

Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraising aarmstrong Tue, 01/25/2022 - 14:00

Pfizer, BioNTech launch trial for potential omicron-busting vaccine

Annalee Armstrong — Tue, 25 Jan 2022 14:29:17 +0000

Pfizer, BioNTech launch trial for potential omicron-busting vaccine aarmstrong Tue, 01/25/2022 - 09:29

Sierra's bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drug

Nick Paul — Tue, 25 Jan 2022 13:10:28 +0000

Sierra's bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drug ntaylor Tue, 01/25/2022 - 08:10

AstraZeneca success torpedoes PCI's pivotal plan, crushing stock

Nick Paul — Tue, 25 Jan 2022 11:23:03 +0000

AstraZeneca success torpedoes PCI's pivotal plan, crushing stock ntaylor Tue, 01/25/2022 - 06:23

89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set

Annalee Armstrong — Mon, 24 Jan 2022 19:51:24 +0000

89bio, trying to rise from ashes of NASH failures, posts gains in disease severity, cardiovascular health in small data set aarmstrong Mon, 01/24/2022 - 14:51

New clinical trial organization launches with promise to conduct randomized trials at fraction of the cost

Annalee Armstrong — Mon, 24 Jan 2022 15:36:17 +0000

New clinical trial organization launches with promise to conduct randomized trials at fraction of the cost aarmstrong Mon, 01/24/2022 - 10:36

1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial

Nick Paul — Mon, 24 Jan 2022 13:26:00 +0000

1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial ntaylor Mon, 01/24/2022 - 08:26

MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year

Nick Paul — Mon, 24 Jan 2022 12:13:01 +0000

MaaT wraps up cancer microbiome trial early to power into phase 2/3 this year ntaylor Mon, 01/24/2022 - 07:13

New research on tau's role in neurodegenerative diseases like Alzheimer's could inform new treatments

Kyle LaHucik — Fri, 21 Jan 2022 18:51:49 +0000

New research on tau's role in neurodegenerative diseases like Alzheimer's could inform new treatments klahucik Fri, 01/21/2022 - 13:51

Alnylam touts data replication for next-generation Onpattro in ATTR trial, but analysts pour some cold water

Annalee Armstrong — Fri, 21 Jan 2022 15:40:56 +0000

Alnylam touts data replication for next-generation Onpattro in ATTR trial, but analysts pour some cold water aarmstrong Fri, 01/21/2022 - 10:40